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ABSTRACT
Using computer simulations, we developed a better understanding of some key
chemical steps of alpha-synuclein aggregation as well as amantadine for drug
delivery systems. The aggregation and fibrillation of alpha-synuclein, a brain
protein of 140 residues, has been linked to several neurodegenerative diseases,
including Parkinson’s and Alzheimer’s diseases. Using molecular dynamics,
α-synuclein, at various temperatures of 293 K, 310 K, 323 K and 348 K, was shown
to undergo rapid conformational change. The non-amyloid-β component (NAC) of
α-synuclein that is not sterically hindered is suspected to undergo aggregation.
Amantadine has been shown to help regulate the symptoms of Parkinson’s disease,
and single-walled carbon nanotubes (SWCNs) could be a potential drug carrier.
Adsorption of amantadine within SWCNs, at differing diameters of 10.9 A˚, 16.3 A˚,
21.7 A˚ and 27.1 A˚, was studied using Expanded Wang-Landau (EWL) simulations.
It was shown that increasing the diameters of the SWCNs increased amantadine
loading - monolayers formed for the two smaller SWCNs while bilayers formed for
the larger. The diffusion process was studied through molecular dynamics. For the
larger two SWCNs, there was a dramatic decrease in the rate of self-diffusion with
respect to increasing amantadine loading followed by a moderate decrease. This was
attributed to the transition from a monolayer to a bilayer structure.
xv
CHAPTER I
INTRODUCTION
1.1 Neurodegenerative diseases
α-synuclein plays a major role in neurodegenerative diseases such as Parkinson’s
disease, dementia with Lewy Bodies, multiple system atrophy, and Alzheimer’s
disease. The three most prevalent diseases in the U.S. will be discussed further, i.e.
Parkinson’s disease, dementia with Lewy Bodies, and Alzheimer’s disease.
1.1.1 Parkinson’s Disease
James Parkinson, a London physician, first identified Parkinson’s disease (PD)
in 1817 when he noticed patients exhibiting involuntary tremors observed especially
in the limbs.24 Parkinson’s disease is defined as a neurodegenerative disorder that
affects movement and coordination. It develops usually after the age of 50 but can
occur earlier. In some cases, PD may be genetic. Currently, it is estimated that
500,000 Americans live with Parkinson’s disease with 50,000 new cases every year.
Due to an influx in baby boomers, these numbers are expected to rise.25,26
The cause of PD is due to its pathological characteristics of Lewy body (LB)
formation and the progressive degeneration of dopaminergic neurons in the
substantia nigra.27 Lewy bodies are alpha-synuclein-immunoreactive inclusions that
are found in the surviving nerve cells of the substantia nigra, see Figure 1 below.6
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Figure 1. A typical Lewy body found in a dopaminergic neuron in the substantia
nigra. The red circle contained in the cytoplasm is the LB.1
A Lewy body is created from an abnormal accumulation of aggregated filaments
which include alpha-synuclein as well as many other proteins involved in proteolysis,
i.e. breakdown of proteins into polypeptides or amino acids, see Figure 2.
Figure 2. A Lewy body showing the accumulation of mainly α-synuclein.1
As mentioned previously, PD is also characterized by the loss of dopamine
releasing neurons. The loss of neurons occurs throughout specific brain regions but
none are more prevalent than in the substantia nigra especially in the pars
compacta. In this region there are approximately 450,000 dopaminergic neurons.
2
The symptoms of PD usually will not occur until 60 to 70 percent of the
dopaminergic neurons have died in this region. The mechanism behind this kind of
cell death is unclear but many believe that Lewy bodies contribute. Growing
evidence suggests that nerve cell death may be apoptotic in the pars compacta
region. This refers to the decomposition of cells into membrane-bound particles
which are removed through phagocytosis or by shedding. However, others suggest
that neuronal degeneration could be a cause of mitochondrial dysfunction, oxidative
stress, action of excitotoxins, deficient neurotrophic support, and immune
mechanisms.1
The major symptoms of PD are described by resting tremors (tremors that
occur when the individual is at rest); symptoms include uncontrollable shaking of
limbs, especially hands and fingers), muscular rigidity, bradykinesia (slowness of
movement) and postural instability.28 In some cases, dementia can occur leading to
Parkinson’s disease with dementia (PDD). As the nerve cells die in the brain,
dopamine is not readily available causing a decrease in fluid muscle movement.
As of yet, there is no cure for Parkinson’s disease, barring the drugs that can
help manage its symptoms. Most of the drugs are used to release dopamine in the
brain. The most common and effective drug is levodopa. Levodopa is transported to
the brain’s nerve cells and is converted into dopamine. This allows the nerve cells to
use it as a neurotransmitter.29
Due to the degenerative nature of Parkinson’s disease, patients may become
completely debilitated. Though PD is not a fatal disease, the secondary
complications may lead to death, i.e. pneumonia, falling, and choking
1.1.2 Dementia with Lewy Bodies
Dementia with Lewy bodies (DLB) is believed to be the second most common
type of degenerative dementia, the first being Alzheimer’s disease, and accounts for
10-15 % of patients with dementia,30 roughly 1.3 million Americans. It mainly
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affects individuals who are over the age of 60. DLB occurs when α-synuclein
aggregates to form insoluble fibrils which are the major contributor to Lewy bodies,
as mentioned previously.31 These Lewy bodies prevent proper cell functioning and
viability.
First identified in the mid-1990s, DLB shares similarities to Parkinson’s disease
with dementia (PDD). The main difference is that in PDD, dementia occurs after
more than one year of parkinsonism while DLP can occur either before,
simultaneously, or within one year of parkinsonism.32
The major symptoms of DLP are cognitive impairment, recurrent visual
hallucinations and parkinsonism.33 Visual hallucinations and delusions are the
result of more abundant Lewy bodies in the temporal cortex than that of PDD.34
Like Parkinson’s disease, there are only drugs that can help with the symptoms;
there is no cure. The most common drugs used are those that are involved with
Parkinson’s disease and Alzheimer’s disease.
1.1.3 Alzheimer’s Disease
Alzheimer’s disease (AD) was identified in 1906 by a German neuropathologist
and psychiatrist Alois Alzheimer. AD is the sixth-leading cause of death and affects
5.3 million Americans.35 This disease also accounts for more cases of dementia than
any other disease.36 Worldwide, it is estimated that over 26.6 million people have
AD and, by 2050, it will quadruple to 106.8 million37
The majority of AD patients is over the age of 65 but it can develop as early as
the patient’s 40’s (early onset AD), although this is more rare. The major risk
factor is age. For people over the age of 65, the risk doubles every five years. By the
age of 85, nearly half of all people are affected. The progression of AD can last up
to twenty years depending on the health and age of the individual.38 Due to the
progressive nature of this neurodegenerative disease, it can be divided into three
main stages: mild, moderate, and severe. In the mild stage, plaques and tangles
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(types of proteins) form in the brain. Here, patients show trouble with memory and
thinking. In the moderate stage, more plaques and tangles are formed causing
significant memory loss. Patients also experience trouble speaking and changes in
personality and behavior. In the severe stage, plaques and tangles have spread to
the cortex. Because of cell death, the brain shrinks. Patients are unable to
communicate coherently and require total assistance for personal care because of the
disease’s debilitating nature.39
Associated with Alzheimer’s disease is the build-up of proteins. There are two
types of protein accumulation: plaques and tangles, see Figure 3. Plaques exist
outside the neurons in the brain while tangles exist inside the neuronal cell. It is
common for these types of proteins to develop in the brain as individuals age, but,
for AD patients, the production is much greater. Although researchers are not sure
what role these proteins play in AD, one suggestion is that they block neuron
signals which make it difficult for the nerve cell to survive.
Figure 3. Plaques and tangles of Alzheimer’s Disease.2
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Plaques of AD consist of Amyloid-β (Aβ) peptides. These peptides are formed
when the amyloid precursor protein, found in neurons, undergoes abnormal
proteolysis, due to a gene mutation. Aβ peptides aggregate in the extracellular
milieu forming toxic soluble oligomers during the first stage of self-assembly. The
Aβ monomers aggregate through multiple pathways and at different rates. The
results are a metastable mixture where oligomeric assemblies are noncovalently
associated. It has been proposed that alpha-synuclein may aid, in some way, in the
aggregation of these peptides.40
In both DLB and AD, it has been shown that cognitive abilities are lost through
synaptic degradation41 and that α-synuclein plays a crucial role in the pathogenesis
of these diseases.42 It has been proposed that misfolded α-synuclein causes this.43
Like the other previous diseases mentioned, there are no cures for AD - only
drugs that can help with the symptoms. The drugs for AD are cholinesterase
inhibitors that help stop the decomposition of neurotransmitters. Still another drug
may be used for the regulation of glutamate by helping block NMDA receptors.
1.2 Self-Assembly
Before delving into the subject of aggregation of α-synuclein, it is important to
first introduce the nature of the protein.
α-synuclein is found mainly in the presynaptic nerve terminal44 and the normal
behavior of this protein is not clearly understood. Some of the presumed functions
include regulation of synaptic plasticity, neuronal differentiation, and dopamine
release, see Figure 4. Synaptic plasticity refers to the synapse’s ability to change in
strength for different responses. α-synuclein has been shown to play a role at
synapses by interacting with brain vesicles and phospholipid membranes.45,46
Neuronal differentiation refers to the ability of α-synuclein to assist in the
development of neurons from other types of cells such as oligofendrocytes or
astrocytes. This has been shown in several different studies.47–49 α-synuclein may
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also inhibit dopamine release due to interactions with vesicle membranes.50 It is
uncertain whether α-synuclein induces cell death (apoptosis) or protects cells.3
Figure 4. Presumed normal function of α-synuclein. ”-” means enzyme inhibition
while ”+” indicates enzyme activation from α-synuclein. The molecules are: PA,
phosphatidic acid; PLD2, phospholipase D2; PKC, protein kinase C; PKA, protein
kinase A; ERK, extracellular-regulated kinase.3
α-synuclein consists of 140 amino acids which can be divided into three main
regions. The first region, residues 1-60, consists of an amphipathic N-terminal
region, which shows an alpha helix structure. Residues 61-95 contain a hydrophobic
region where aggregation usually occurs. The third region, residues 96-140, contains
a highly acidic C-terminal,51 see Figure 5 below.
The synthesis of α-synuclein is encoded by the SNCA gene, synuclein, alpha
(non a4 component of amyloid precursor). Problems can occur when the synthesis
of α-synuclein leads to a mutated form or an excess of the protein. Mutations of
α-synuclein, resulting in a misfolded configuration, occur when alanine is replaced
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Figure 5. α-synuclein showing turns, beta bridges, bends, and alpha helices. Letters
represent amino acids.
by another amino acid at positions 3052 or 53.53 SNCA can also be inappropriately
duplicated or triplicated resulting in excess α-synuclein.54 When α-synuclein is in
its mutated form or when there is an excess, it becomes a toxic protein since
α-synuclein can act as a nucleation/seeding agent for aggregation.55 This leads to
an increase in neuronal cell death which causes the various neurodegenerative
diseases. Therefore, understanding the mechanism behind aggregation is crucial as
it could allow for drug development for the various diseases.
The aggregation mechanism that produces insoluble forms of α-synuclein is
unknown.56 Prior work has shown that aggregation starts when α-synuclein
undergoes a conformational change to form a partially folded intermediate. Several
of these intermediates may then aggregate to form oligomers, amorphous aggregates
or fibrils.57 This aggregation leads to Lewy body formation which has been
mentioned previously. A representation of the different stages of folding for
α-synuclein can be seen in Figure 6.
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Figure 6. α-synuclein in different stages of aggregation4
A general overview of the aggregation and the events leading to toxicity can be
seen in Figure 7. The middle column shows the main pathway of aggregation.
Here, α-synuclein is natively unfolded and can bind to membranes or start forming
oligomeric species. These oligomers are then stabilized by β-sheet-like interactions.
Later, this will turn into insoluble fibers leading to Lewy bodies. The left column
contains known modifiers that have been shown to increase the aggregation process.
In the right column are cellular structures that have been suggested to be affected
by the aggregation of α-synuclein.5
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Figure 7. Pathway of α-synuclein aggregation leading to toxcicity to proposed cellular
structures.5
Behind aggregation, there are a number of different factors that could lead to
cell death as can be seen in the outline of Figure 8. We will discuss a few of these
factors that can lead to an increase in aggregation.
The first factor that could increase aggregation is protein mutation. Comparing
the A30P and A53T mutations with wild-type (WT) α-synuclein, it was
demonstrated that the rate at which aggregation occurred was fastest for the A53T
mutant, followed by the A30P mutant and finally, the WT α-synuclein.58 It was
shown that A30P formed fibrils at a slower rate than the other two.59 However,
A30P formed oligomers that could even be more toxic than fibrils. This mutation
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Figure 8. Possible mechanisms behind α-synuclein aggregation. The molecules are
described by: PA, phosphatidic acid; PLD2, phospholipase D2; ERK, extracellular
regulated kinase; WT, wild type; A30P and A53T are α-synuclein mutations.3
also led to α-synuclein’s inability to bind to vesicles. Becuase α-synuclein could no
longer do its normal function, it has been thought that this could lead to an
increase in concentration within the cell body. This accumulation could lead to
aggregation, which would result in the formation of Lewy bodies.45
The second factor is truncation. The truncated form of α-synuclein, i.e.,
residues 1-120, were found to be more likely to form filaments compared to that of
the full α-synuclein, i.e., residues 1-140.60
The occurrence of metal ions is the third factor. One example is the Fe3+ ion.
It was shown that if these ions were found in the substantia nigra, there was an
increase in aggregation of α-synuclein.61 Finally, it was shown that Aβ25-35
fragments promotes oligomerization of α-synuclein.62
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After fibrillization has occurred, Lewy body formation will appear. Lewy bodies
are made up of filaments that are between 7 to 15 nm long and arranged either
radially or randomly. This abnormal accumulation can be either age or disease
related. They are found within the substantia niagra, although finding them in
brainstem neurons are one of the diagnostic criteria for Parkinson’s.63 Due to this
feature, their structure and composition (found by staining with eosin) may change
slightly. LBs are found within the cytoplasm of the cell (intracytoplasmic). Most
LBs are round (between 5 to 25 µm) and surrounded by a halo when stained, see
Figure 9 below. Some Lewy bodies occur elongated or are complex in shape.64
Also, some will exhibit darker centers (cores) and/or darker rings (laminae).
Figure 9. A LB showing the core (C), body (B), and halo (H).6
1.3 Outline
This thesis will be divided into several parts. The first will include recent
experimental and molecular simulation results. Next, the basis of molecular
dynamics as well as key properties will be discussed. Then, α-synuclein, in a system
of water and ions, will be looked at. Finally, the latter will lead into using computer
simulations for potential drug delivery systems, specifically amantadine and carbon
nanotubes.
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CHAPTER II
STATE OF THE ART
2.1 Recent experiments/treatments
As mentioned previously, the accumulation of α-synuclein and Lewy body
formation are the attributes of various neurodegenerative diseases. The progressive
nature of these diseases is a direct result of the spread of Lewy pathology. For
example, in PD patients, α-synuclein aggregation starts in the lower brainstem and
olfactory bulb and spreads into the limbic system and finally into the neocortex.65 It
has been shown that the spreading, which could be a result of pathological
propagation, of the Lewy pathology, can occur from a host tissue to grafted neurons
within the brains of PD patients.8,66,67 However, the mechanism behind the
spreading is unknown and will be further looked at through recent experimental
studies.
α-synuclein was thought to be an intracellular protein localized mainly in the
the cytosol with a small portion found in vesicle fractions.68,69 However, later
α-synuclein was found in human CSF and blood plasma.70,71 Due to these findings,
α-synuclein secretion from the cell through exocytosis was investigated. It was
found by Lee et al. that the small portion of the protein contained in the lumen of
vesicles could be released through an unconventional exocytic pathway.
Additionally, the α-synuclein found in the vesicles was more prone to aggregation
and this aggregated substance could also be secreted.7
Overexpression of human α-synuclein in differentiated SH-SY5Y human
neuroblastoma cells was shown to release the protein in a culture medium after 2
hours and accumulated thereafter, see Figure 10. This proposes that α-synuclein is
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constitutively secreted by exocytosis. Lee et al. then showed that the release of the
protein was not due to byproducts of overexpression or to leakage of the membrane
due to a dying cell by the following: (1) when the protein, β-galactosidase, was
overexpressed in SH-S5Y, it was not discovered in the medium, unlike α-synuclein;
(2) there was a clear correlation to the amount of α-synuclein released to that of
intracellular expression levels; (3) when α-synuclein was followed over time by pulse
labeling with 35S, the quantity of the protein in the medium reached a saturation
point in 2 hours. This signifies that the secretion of α-synuclein could not be due to
membrane leakage as there would be a continuous supply of this protein in the
medium; (4) α-synuclein that had been secreted was found in the medium
containing rat primary cortical neurons. This suggests that neuronal endogenous
α-synuclein can also be constitutively released.7
Figure 10. Secretion of α-synuclein using Western blotting. The whole-cell extracts
(ext) and medium (med) were obtained at the designated times.7
Exocytosis is inhibited by low temperature, which is a classical blocker for
vesicular exocytosis. To determine if the α-synuclein released was mediated by this
process, SH-SY5Y cells, which had an overexpression for α-synuclein, were incubated
at two different temperatures, 18◦C or 37◦C. At 18◦C, the release of α-synuclein was
greatly reduced indicating that its secretion is due to exocytosis, see Figure 11.7
The mechanism behind α-synuclein release into a medium is uncertain. It was
shown that α-synuclein lacks a signal sequence, which was somewhat unusual since
it still could be secreted from the cell. Other studies have shown that similar
proteins that lack a signal sequence could be secreted from the cell through
nonclassical vesicular exocytosis.72,73 These proteins are resistant to BFA, which is a
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Figure 11. The release of α-synuclein is blocked at low temperature, i.e. 18◦C. The
whole-cell extracts (ext) and medium (med) were obtained at 3 hours. Results were
obtained through Western blotting.7
classical inhibitor of endoplasmic reticulum (ER)/Golgi-dependent protein secretion.
SH-SY5Y cells that expressed α-synuclein were studied with and without BFA.
α-synuclein was pulse labeled with 35S so it could be tracked. It was shown that in
the presence of BFA, α-synuclein secretion was greatly reduced, showing that the
classical export pathway was disrupted. However, the protein was still released
indicating that the secretion is from an unconventional export pathway, which is
ER/Golgi-independent, see Figure 12.7
Figure 12. BFA does not block the secretion of α-synuclein. Thus, there is some
other type of secretion mechanism that does not rely upon ER/Golgi-related classical
vesicular transport.7
Aggregation of α-synuclein in three different brain fractions, i.e. P3 (
microsomal vesicles), LP2 (crude synaptic vesicles) and S3 (cytosol), were observed.
It was found that high-molecular-weight aggregates occurred more quickly in P3
and LP2 vesicle fractions than in S3, see Figure 13. It was also shown that the
vesicles from SH-SY5Y cells had an increase in aggregation rate, which had been
created from the intravesicular α-synuclein instead of cytosolic contaminants or
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vesicle-surface-bound α-synuclein, compared to that of the cytosol. This was also
found to be true in intact cells of SH-SY5Y, see Figure 14. The aggregation of
α-synuclein occurs faster in the vesicle lumen than that of the cytosol.7
Figure 13. S3, P3, and LP2 brain fraction aggregation rates for α-synuclein. The vesi-
cles, i.e. P3 and LP2, had an increase in aggregation compared to that of the cytosol,
i.e. S3. The bracket indicates high-molecular-weight aggregates, while the arrow-
head indicates monomeric α-synuclein. Aggregation was observed through Western
blotting.7
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Figure 14. Vesicles, V, versus cytosol, C, aggregation. A bracket indicates high-
molecular-weight aggregates, an arrowhead indicates monomeric α-synuclein, and an
asterisk indicates an side protein that cross-reacts with Syn-1 antibody.7
It has been shown that at low levels of α-synuclein expression in SH-SY5Y cells,
only monomeric α-synuclein is present in both cell extracts and in the medium. At
higher levels, α-synuclein aggregated within the cell and the accumulated mass was
secreted, see Figure 15A. Like that for α-synuclein, aggregates of α-synuclein were
secreted through exocytosis since inhibition occurred at low temperatures, i.e., a
classical blocker for vesicular exocytosis, see Figure 15 B.
So far, we have been discussing α-synuclein secretion through an exocytosis
pathway. We will now consider the uptake of the protein through endocytosis.
Extracellular α-synuclein aggregates (fibrils, oligomers, and monomers) were
studied since they have been shown to cause neurotoxicity to surrounding cells. It
was demonstrated that these aggregates were internalized through endocytosis,
which ultimately led to the degradation of the proteins. The internalization of fibrils
was demonstrated to go through endocytosis-mediated internalization since the
uptake of α-synuclein from a cultured medium could be blocked by both low
temperature and the expression of dynamin-1 K44A, which is a dominant-negative
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Figure 15. (A) Release of α-synuclein at increasing levels of expression in SH-SY5Y.
Proteins released were collected for 16 hours. A bracket indicates high-molecular-
weight aggregates, an arrowhead indicates monomeric α-synuclein, ”ext” indicates
whole-cell extracts and ”med” indicates the conditioned medium. (B) Release of
α-synuclein aggregates is blocked at low temperature.7
mutant. Once internalized, the fibrils migrated through the endosomal pathway and
were degraded within the lysosome. Similarly, oligomers were internalized through
endocytosis and were degraded by the lysosome. Monomers were shown to be
impervious to low temperature and dynamin-1 K44A signifying the direct
translocation across the plasma membrane. The monomers are then degraded by
the cellular proteolytic system. These discoveries may imply that the removal of
extracelluar aggregates of α-synuclein occurs through the, uptake of the aggregates
through endocytosis, followed by a transportation of the endosomal pathway and
then finally degraded by lysosomes.74
There have been investigations on transplantation of neurons into patients with
Parkinson’s disease that have shown, years later, i.e., between 11 and 16 years, that
the grafted cells tested positive for α-synuclein and contained Lewy body-like
inclusions.66,67 This observation demonstrates that progression of α-synuclein can
occur from host to grafted neuron cells.
Since previous studies have shown that neurons are capable of internalizing
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extracellular aggregates of α-synuclein through endocytosis,74 mouse cortical
neuronal stem cells (MCNSCs) were tested to determine if a similar process could
occur. Through Western blotting and immnofluorescence, it was determined that
MCNSCs could internalize extracellular aggregates of α-synuclein.8 MCNSCs were
incubated with a medium consisting of Alexa-Fluor-488-labeled α-synuclein. Figure
16 illustrates the internalization of extracellular α-synuclein in mice stem cells.
Figure 16. MCNSC uptake of the fluorescent tagged α-synuclein (green) found outside
the stem cell.8
The transmission of α-synuclein from host cells to grafted MCNSCs were
studied in vivo. MCNSCs were labeled with the green fluorescent protein, GFP, and
were subsequently placed into transgenic mice brains, which expressed α-synuclein,
via stereotaxic intrahippocampal injection. After 1 week, 2.5% MCNSCs had taken
up α-synuclein, see Figure 17 A, while after 4 weeks, 15% of MCNSCs had
significant levels of α-synuclein. A few of the MCNSCs, 2.5% of total injected stem
cells, after 4 weeks displayed Lewy-body like inclusions, see Figure 17 B. For
nontransgenic mice that were injected with MCNSCs, no inclusions were found. It
was also determined that after 1 week, transgenic mice showed mild inclusions in
the MCNSCs and this number grew as time progressed, up to 4 weeks. Compared
to mice that had no expression towards α-synuclein, no α-synuclein was found in
the MSNSCs, see Figure 17 E. Therefore, it is suggested that without an expression
for α-synuclein, the protein will not propagate from neuron to neuron, Figures 17 C
and D.8
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Figure 17. (A) α-synuclein (red) found in transgenic mice were later found in the
grafted MCNSCs that were labeled with GFP (green, arrows). (B) After 4 weeks,
some MCNSCs displayed an inclusion body that tested positive for α-synuclein. (C)
Transgenic mice that had no injection of MCNSCs. (D) Nontransgenic mice that were
injected with MSCNSs. No α-synuclein was found in the stem cells. (E) α-synuclein
was shown to propagate from the host cells of transgenic mice that had an expression
of α-synuclein to MCNSCs. In nontransgenic mice, α-synuclein was not transferred.8
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Similarly, human dopaminergic neuron cells were cocultured in vitro to study
the effects of cell-to-cell transmission. One group of cells was expressed with
myc-tagged-α-synuclein, i.e. donor cells, while the other group’s cells were labeled
with Qtracker and had no expression of α-synuclein, i.e. acceptor cells. It was
shown that α-synuclein was transmitted from the donor cells to the acceptor cells
after 24 hours, Figure 18 A. With this, it was demonstrated that there was a
correlation between the expression levels of α-synuclein in the donor cells to that of
the acceptor cells that contained the transferred protein, see Figure 18 C, left
panel. In some instances, inclusion bodies formed near the nucleus, Figure 18 B, in
proportion to the donor’s expression levels, Figure 18 C, right.8
Figure 18. (A) α-synuclein (green) found in the acceptor cells (red) that was trans-
ferred from donor cells. (B) Inclusions (arrows) found in acceptor cells. (C) Left,
percentage of α-synuclein transferred to the acceptor cells within 3 days. Right, per-
centage of α-synuclein found in acceptor cells. Error bars correlate to: ∗, P < 0.05;
∗∗, P < 0.01.8
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α-synuclein causing apoptosis in neurons is unknown. Studies of neuron
transplantation in humans showed no apparent cell death.67,74,75 Desplatsa et al.
studied the effects of endoyctosed α-synuclein in vitro by allowing rat primary
cortical neurons, MCNSCs, to exist in the presence of of a medium consisting of
either α-synuclein or β-galactosidase (LacZ medium). Figure 19 illustrates their
findings. Cells existing in the α-synuclein medium showed neuronal degeneration
due to the observed nuclear fragmentation and caspase 3 activation. The longer the
time period, the more neuronal cells were killed. In the LacZ medium, the neurons
indicated no nuclear fragmentation and there was a negligible increase in caspase 3
activation, Figure 19 A and B. Then, an in vivo study was done by injecting
MCNSCs into the hippocampus of transgenic mice exhibiting human α-synuclein.
During 4 weeks, MCNSCs had an increase in activated caspase 3 immunoreactivity.
When tested amongst nontransgenic mice, there was no activation of caspase 3,
Figure 19 C. These results were also found to be true for recombinant α-synuclein
found outside the cell.76 However, these results are based on overexpression for
α-synuclein.
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Figure 19. (A and B) Neuronal cell death in two different mediums: SH-SY5Y cells
overexpressing either α-synuclein or β-galactosidase (LacZ medium). (A) Nuclear
fragmentation observed. (B) Activation of caspase 3 observed through immunofluo-
rescence. Error bars correlate to: ∗, P < 0.05; ∗∗, P < 0.01. (C) caspase 3 activation
in MCNSCs when injected into either transgenic mice showing an expression for hu-
man α-synuclein or nontransgenic mice.8
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2.2 Recent molecular simulation results
Advancements have been made to understand the molecular mechanisms behind
aggregation through in vitro studies. However, it has not been until recently that
computer simulations have aided in the understanding of the role of different
proteins in the aggregation causing neurodegenerative diseases. The reason for not
implementing studies using computer simulations sooner was due to the need for
lengthy timescales as well as large system sizes.10 Computer simulations were first
used for small peptides but, with a better understanding of protein interactions and
system requirements, have grown to simulating many proteins, which help in better
understanding the aggregation process. We will discus recent molecular simulations
that have aided in a better understanding of neurodegenerative diseases.
It has been suggested the abnormal accumulation of α-synuclein, which is
natively unfolded, may contribute significantly to the aggregation found in Lewy
bodies. These aggregates are due to a partially folded intermediate, i.e. α-synuclein
monomers, that get converted into oligomers and later annular protofibrils and
pore-like structures.77,78 It has been hypothesized that oligomers, rather than fibrils,
are the agents leading to neuronal cell death.59 However, little is known about the
mechanism of transforming α-synuclein into oligomers at the early stages of
aggregation.
Tsigelny et al. investigated the dynamics of α-synuclein during the beginning of
α-synuclein aggregation and the possible role of β-synuclein on the prevention of
aggregation using molecular modeling and molecular simulations. They first
subjected the two proteins, separately, to a simple system consisting of water in
order to study the effects of structural changes to the the different proteins. For the
starting structure of α-synuclein, the PDB file, 1xq8, was used as it was predicted
that it would more easily result in oligomerization. This file contained the
micelle-bound α-synuclein structure obtained through NMR.79 β-synuclein was
created using the homology module of the INSIGHT II program and was then
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minimized for 10,000 iterations using the DISCOVER program.
α-synuclein contains two regions within the curved N-terminal domain, i.e.
helix-N and helix-C. The angle between these two regions at the start was 55 ±3◦,
after 2.0 ns it decreased to around 42-44◦, and then increased after 5.0 ns to 64-70◦,
see Figure 20 A and B. During the 5.0 ns, the N-terminal region converted from the
two curved helical domains into three uncurved helical structures. This resulted
when the second curved helix (aa 46-84) transformed into uncurved helix 2 (aa
46-63) and uncurved helix 3 (aa 74-84). These findings demonstrate that
α-synuclein developed into a different three-dimensional shape (because of the
movement of the C-terminal region compared to that of the N-terminal region) and
that the helical structure that α-synuclein assumed was highly stable due to the fact
that it never returned to its natively unfolded state.9
Figure 20. α-synuclein and β-synuclein transfomrations through molecular dynamics.
(A) Structural changes of α-synuclein at different times in the simulation. Simulation
was done in a simplified system of water. (B) Superimposed images of α-synuclein
at aa 1-15.(C) Structural changes of β-synuclein at different times in the simulation.
Simulation was done in a simplified system of water. (D) Superimposed images of
β-synuclein at aa 1-15.9
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When comparing α-synuclein to β-synuclein, they found that β-synuclein did
not undergo a transformation at the second helix to form the two distinct helices,
though sharing a similar structure to that of α-synuclein. Rather, β-synuclein’s
curved helices converted into a nearly straight configuration after 2.0 ns. The angle
of the N-terminal helices varied as well as the motility of the C-terminal tail, noting
that β-synuclein’s tail provided greater motility than that of α-synuclein’s. Finally,
the stability of the β-synuclein monomer increased from 2.0 to 3.5 ns.9
α-synuclein aggregation was studied through membrane docking. Two initial
conformations of the protein were docked on a flat surface without providing
limitations. ’Head-to-tail’ low energy configurations formed, Figure 21 A and B.
These complexes were named due to their interactions, i.e. mainly electric charge, of
the amino acids of one α-synuclein’s N-terminal domain with the amino acids of the
C-terminal domain of the second protein. These homodimers may interact with
additional monomers of α-synuclein but this is unlikely resulting in a lack of higher
order aggregates. This is because the homodimers restrict the amount of low-energy
docking sites needed for successive docking. Because of the lack of propagation
towards higher order aggregation, these head-to tail complexes were described as a
nonpropagating dimer.9
Figure 21. Nonpropagating (head-to-tail) α-synuclein dimers on a flat surface without
explicit limitations. (A) Minimal energy of the head-to-tail α-synuclein dimers. (B)
α-synuclein monomers are arranged in the head-to-tail configuration which prevents
low-energy docking of more α-synuclein.9
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Additionally, α-synuclein monomers were studied on a membrane surface. The
surface used was 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
membrane. The protein’s surface, i.e. membrane-contacting, was faced towards the
membrane. This resulted in α-synuclein’s N-terminal helices to be distributed along
the membrane as can be seen in Figure 22 A. Figure 22 B illustrates the docking of
two α-synuclein monomers onto the POPC membrane.9
Figure 22. Docking of α-synuclein. (A) Docking of α-synuclein to the membrane’s
surface at 4.0 ns. Orange depicts the residues in contact with the membrane. (B)
Two conformers of α-synuclein at 4.5 ps docked onto the POPC membrane.9
Normally, two different complexes would form when docked to the membrane:
head-to-tail and head-to-head. Like that for a flat surface, the head-to-tail
configurations were not likely to propagate into higher order aggregates since
low-energy binding sites were not common. The head-to-head configuration made it
possible for additional propagation, i.e., more low energy binding sites, thus known
as the propagating dimer. Low-energy binding sites became available, possibly due
to an increase in intermolecular interactions. Comparing the conformations that
ranged from 1.5 to 5.0 ns, it was observed that for longer simulation times, i.e.,
greater than 4.0 ns, an increase in residues on the C-terminal tail, which contained
mostly the positive charge of the protein, were involved in intermolecular
interactions. This, possibly, resulted in the ability to form lower docking energies.
Table 1 shows the intermolecular interaction energies involved when dimers of
α-synuclein were docked to the POPC membrane at different timer intervals.
27
Because of the ability to propagate, when similar low energy α-synuclein proteins to
that of the propagating dimer were added consecutively, energetically favorable
higher order aggregates formed, i.e. trimers, tetramers, pentamers, and hexamers.9
Table 1. Electrostatic energies involved in propagating dimers of α-synuclein that
were docked onto the POPC membrane. MD, molecular dynamics.9
MD time (ns) Electrostatic energy (kcal·mol−1)
1.50 -10.6
2.00 -10.6
2.50 -13.4
3.50 -15.1
4.00 -19.7
4.50 -32.9
When the most likely multimers of α-synuclein were chosen (based off of
favorable energies), it was found that six configurations formed at different time
periods, see Figure 23.9 These multimers developed ring-like structures which
appeared to be similar to those found using atomic force microscopy.77
Figure 23. Simulations via molecular dynamics of multimers at different time periods.
Table on right indicates the inner diameters (ID) and outer diameters (OD).9
Because the amyloid diseases, for example, Parkinson’s and Alzheimer’s
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diseases, occur due to the slow progression of proteins aggregating to form plaques
and tangles, this was studied computationally via molecular dynamic simulations.
Simulation of fibrils were done by using the protein model, Protein
Intermediate-Resolution Model (PRIME) coupled with discontinuous molecular
dynamics (DMD). Polyalanine peptides containing 16 residues in a random-coil
state were chosen since they (1) were the simplest peptide recognized to form fibrils
undergoing a change from an α-helix structure to a β-sheet structure and (2)
contained simple sidechain structures creating simplicity for modeling.10
Fibrillization occurred by first forming amorphous aggregates. These
aggregates, through time, became rich in β-sheet structure. Finally a nucleus for
fibrillization occurred. The fibrillization process can be seen in Figure 24. The
simulation consisted of 48 peptides at reduced times, t∗, constant temperature,
T ∗=0.14, and constant peptide concentration of 10 mM. Small amorphous
aggregates form from a random coil state that can be seen at t∗=0. The aggregates
grow, t∗=10.0, until they morphed into one large aggregate at t∗=12.0. One
aggregate with a β-sheet formed after the large aggregate broke into smaller
aggregates at t∗=14.6. This is exemplified as the purple sheet on the lower-right side
of the snapshot. The broken aggregates, at t∗=36.1, have become β-sheets,
light-blue, white, and dark-blue, while the first β-sheet, purple, has grown. Two of
the β-sheets, i.e. light-blue and white, have merged resulting in a two-sheet fibrillar
structure at t∗=40.2. This structure grows as the purple and dark-blue sheets join,
t∗=49.7. Finally, at t∗=205.9, the final fibrillar structure is stable and continues to
grow as more peptides become attached to the ends of the β-sheets.10 These
findings were found to be typical, experimentally, as first proteins join together to
form aggregates, than develop a critical nuclei, and finally grow into large fibrils.80
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Figure 24. Snapshots of the fibrillization process.10
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Proteins that are involved in fibril formation, i.e. plaque formation, are small
peptides known as amyloid-β (Aβ) with 40 (Aβ1−40) or 42 (Aβ1−42) residues.
Proteolytic cleavage, which occurs in Alzheimer’s disease, creates smaller fragments
which are amyloidogenic and toxic. Studying the kinetics of smaller peptides
forming amyloid plaques is much like that for their larger counterpart. By examining
the role of these peptides, the overall amyloid formation may be better understood.
Nussinov and coworkers studied small amyloid-β peptides with high temperature
molecular (MD) simulations in the hopes of understanding the structures that form,
particularly multilayer β-sheet oligomer organizations. They studied three different
fragments: Aβ16−22, Aβ16−35, Aβ10−35 but only Aβ16−22 will be looked at here.11
Octamers of Aβ16−22 were simulated using three parallel (two of which the two
layers are parallel, and one of which the two layers are antiparallel) and two
antiparallel orientations, Figure 25.11
Figure 25. Arrangement of the starting structures simulated for Aβ16−35.11
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It was determined that Parallel 1 and Parallel 2 dissociated within 1 ns at 330K
due to the large rms deviation (rmsd). This was due to weak interactions between
the parallel β-sheet layers. This arrangement was therefore considered not to
contribute significantly to the formation of amyloid fibrils. However, Parallel 3 was
shown to have greater stability than the other two. Two 3−ns simulations were run.
One simulation indicated that the structure remained in a stable β-sheet cluster
while the other showed the β-strands separating within the layer. Still, the rmsd of
Parallel 3 was substantially lower than those of Parallel 1 and Parallel 2.
The antiparallel arrangements were found to be of a higher stability than all
parallel arrangements. Antiparallel 1, which consisted of antiparallel
sheets/antiparallel layers, had slight deviations from each other when run in two
independent simulations at 330 K. Antiparallel 2, which consisted of antiparallel
sheet/parallel layers, had insignificant deviations from each other. This arrangement
was also shown to be the most stable of all the configurations. The stability could
come from salt bridges but more than likely it was due to hydrophobic interactions.
Therefore, for Aβ16−22, both parallel and antiparallel β-sheet configurations could
occur but the antiparallel β-sheet orientation was the most common and the most
stable.11 This was in agreement to previous solid state NMR data.81
The simulations provided by Nussinov and coworkers are helpful in that they
provide the stabilities of certain Aβ arrangements, but this does not reveal the
aggregation process for these peptides. Santini et al. investigated this phenomenon
with three Aβ16−22 peptides via the activation-relaxation technique (ART) and a
generic energy model, OEP. In randomly selected Studies of neuron transplantation
in humans showed no apparent cell death states, the most stable structure, i.e.
antiparallel orientation, was found to superimpose within 1 A˚ rmsd of its
arrangement when found in fibrils. The complete structural order of the peptides
within the fibrils needed larger aggregates since the structure was in equilibrium
with antiparallel β-sheets and mixed parallel-antiparallel β-sheets. Finally, folding
occurred when dimers formed with the consecutive addition of monomers. Folding
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continued through a common mechanism between disordered and native alignments
of β-strands.82
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CHAPTER III
MOLECULAR DYNAMICS
3.1 Gromacs
GROMACS, GROningen MAchine for Chemical Simulations, is a computer
software package aimed to run molecular dynamics mainly on biomolecules such as
proteins, lipids, and nucleic acids. It was designed at the University of Groningen
and is now maintained by many universities worldwide.
GROMACS has many advantages that make computer simulations for
α-synuclein simple compared to other methods. This package is free and open
source allowing for anyone to be able to use it since it is also user-friendly. For
example, topologies and run parameters are written in a clear text format and error
messages are given if something is inaccurate. Also, it has a graphical user interface
and the option -h can be used if help is needed about different tools. It runs on
both CPUs (Central Processor Unit) and GPU (Graphics Processing Unit).
GROMACS has an exceptional high performance compared to other software
packages since the code is optimized. It can also be run in parallel by using the
standard MPI communication. GROMACS also contains different force fields and
many different trajectory analysis resulting in not having to write codes83
3.2 Molecular Dynamics
Molecular Dynamics (MD) simulations have become a powerful computational
tool because it can simulate a large variety of systems. MD is performed in much of
the same way as real world experiments. For example, a sample must be prepared
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and a tool must be used to measure a property. If there is statistical noise, the
longer the average measurement, the more accurate the results. In our case, we
prepared our system: alpha-synuclein, water molecules, and ions. Solving Newton’s
equations of motion until the properties of the system no longer change over time
equilibrates the system.84 Newton’s equations of motion for a system can be
described by equation 3.1.13
Fi = mi · ai = mi · dvi
dt
= m · ∂
2ri
∂t2
, i = 1...N (3.1)
where N is the number of interacting particles, m is the mass of atom i, r is the
position of atom i as a function of time, and t is time. The force on atom i can is
described by equation 3.2
Fi = −∂V
∂ri
(3.2)
where force is the negative derivative of a potential function.13 After this
equilibration, where temperature and pressure remain at the set values, results can
be obtained.
Molecular Dynamics can be illustrated by the following flow chart, see Figure
26.
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Figure 26. Simplified flowchart of Molecular Dynamics. Note, force should be the
negative gradient of the potential.12
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MD is first started by (1) inputting initial conditions. This includes the
potential interaction V , positions r, and velocity v, of all atoms in the system.
Next, (2) forces are computed. Forces on any atom (see equation 3.2) are
calculated by: determining both the force on any non-bonded pairs, forces due to
bonded interactions, restraining forces, and external forces. The force on any
non-bonded pair can be described by equation 3.3
Fi =
∑
j
Fij (3.3)
Potential energy, kinetic energy, and pressure tensor are also calculated at this
point. Then (3) the configuration is updated by solving for Newton’s equations of
motion (see equation 3.1). Finally, (4) the output is written. For example, this
could include positions, velocities, energies, temperature, and pressure. This
procedure is done iteratively until the required number of steps is met.13
3.2.1 Integrators
Integrators have been created in order to integrate Newton’s equations of
motion. There have been many different algorithms to do this but the most
common is the Verlet integrator, which is usually the simplest and the best.
However, we used the leap-frog integrator for studying α-synuclein in water, which
is equivalent to the Verlet integrator. The Leap Frog algorithm calculates the
velocities v at half-integer time steps t− 1
2
∆t to evaluate the new positions r. The
velocities at half-integer time steps are defined by equations 3.4 and 3.5.
v(t− ∆t
2
) ≡ r(t)− r(t−∆t)
∆t
(3.4)
v(t+
∆t
2
) ≡ r(t+ ∆t)− r(t)
∆t
(3.5)
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Based on the old positions and velocities, we attain equation 3.6 for the new
positions based on equation 3.5
r(t+ ∆t) = r(t) + ∆tv(t+
∆t
2
) (3.6)
In order to update the velocities, the Verlet algorithm is utilized giving equation
3.7. Therefore, by using the forces f(t) determined at the new positions, the
positions and velocities are updated.
v(t+
∆t
2
) = v(t− ∆t
2
) + ∆t
f(t)
m
(3.7)
The Leap Frog algorithm, because of being derived from the Verlet algorithm,
will produce identical trajectories, see equation 3.8. However, the velocities are not
determined at the same time as the positions. Due to this, the total energy cannot
be calculated because both the kinetic and potential energy are not determined at
the same time.13,84
r(t+ ∆t) = 2r(t)− r(t−∆t) + 1
m
f(t)∆t2 +O(∆t4) (3.8)
The trajectory of the Leap Frog algorithm can be seen in Figure 27 where the
positions and velocities are jumping over each other, much like how frogs leap over
each other’s backs.13
For studying carbon nanotubes, symplectic integrators developed by Martyna et
al. were used [56, 57].
3.2.2 Velocity Generation
Velocity generation is used to assign velocities to different particles. This is
done by utilizing the Maxwell distribution at the given temperature. A simple
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Figure 27. Leap-frog integrator.13
illustration of Maxwell’s distribution can be seen in Figure 28. As the temperature
increases, the distribution is shifted to higher velocities and is broadened at higher
temperatures. A random seed (gen seed) is also used to give random velocities by
using a random generator.13
Figure 28. Maxwell distribution.14
3.2.3 Energy Minimization
Energy minimization is used to find a potential energy minimum near the
starting structure. This is done to ensure no steric clashes or inappropriate
geometries and to ”relax” the system. If this is not done, the simulation could
crash. Within GROMACS, three different methods may be used: steepest descent,
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conjugate gradients, or l-bfgs (limited-memory Broyden-Fletcher-Goldfarb-Shanno
quasi-Newtonian minimizer). We chose the steepest descent as the algorithm as it is
robust and brings the protein to the nearest local minimum very quickly; however,
the conjugate gradient algorithm is slower but brings the protein very near to the
minimum energy.
The steepest descent algorithm works by first calculating both forces and
potential energy. Next, a maximum displacement, hn, is applied and new positions
of the force and potential energy are found. This is described in equation 3.9
rn+1 = rn +
Fn
max(|Fn|)hn (3.9)
where vector r is the vector used to define the 3N coordinates and Fn is the
force, i.e. negative gradient of the potential. This process is repeated over and over
again as long as the move is accepted. New positions occur when Vn+1 < Vn which
results in hn+1 = 1.2hn. Rejected positions occur when Vn+1 ≥ Vn which results in
hn = 0.2hn.
The minimization of energy stops when either the simulation has reached the
number of force evaluations specified or the absolute value of the force term is
smaller than a specified value .  may be described through the root mean square
force f that a harmonic oscillator would exhibit at temperature T , equation 3.10,
f = 2piυ
√
2mkT (3.10)
where υ is the oscillator frequency, m is the reduced mass, and k is the
Boltzmann constant.?
Energy minimization was ran using the GROMACS MD engine, mdrun.
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3.2.4 Equilibration
Equilibration is used to obtain a state of equilibrium between the ions, solvent,
i.e. water, and α-synuclein. If this was not done, the system could potentially
collapse. Therefore, the solvent and ions are placed around the protein based on the
temperature. Here we wished to study the protein at four different temperatures:
293K, 310K, 323K, and 348K; where 310K is the average human body temperature.
We conducted this first phase in the NVT ensemble, also known as the
isothermal-isochoric or canonical. Once the solvent reached equilibrium with the
protein at the different temperatures, pressure was applied in order to obtain proper
density. This second phase was conducted in the NPT ensemble, also known as
isothermal-isobaric. Like the energy minimization step, equilibration was run using
mdrun.
3.2.5 Periodic Boundary Conditions
Because we are simulating a system that is relatively small, there is a lot of
unwanted boundary with its environment, i.e. vacuum. Our goal is to simulate a
large system of water and α-synuclein. In order to circumvent this problem, we used
periodic boundary conditions.
Periodic boundary conditions are able to create no boundaries between the
system and surroundings by first creating the system within a box. This box is then
duplicated many times and the system is surrounded by these many boxes. A
scheme of periodic boundary conditions in two-dimensions can be seen in Figure
29. We used periodic boundary conditions in all directions.
GROMACS combines periodic boundary conditions with the minimum image
convention. This is when short-range non-bonded interaction terms are applied to
the closest image of one particle. This method is not accurate for long-range
electrostatics so lattice sum methods such as Ewald Sum, PME, and PPPM are
applied.
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Figure 29. Periodic boundary conditions.?
We used a unit cell as our system. This box is defined by the box vectors a, b
and c. In order for GROMACS to be able to use these vectors, they must satisfy
the following criteria:?
ay = az = bz = 0 (3.11)
ax > 0, by > 0, cz > 0 (3.12)
|bx| ≤ 1
2
ax, |cx| ≤ 1
2
ax, |cy| ≤ 1
2
by(3.13)
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3.2.6 Neighbor Searching
Because calculating the energy of the system is expensive timewise, determining
what particles do not contribute to the energy of a single particle is important. This
is known as neighbor searching.
Non-bonded pair forces are calculated for pairs, i, j, as long as the distance rij
between them is less than a the radius criteria, Rc. The only case in which
non-bonded forces are calculated even if it is less than Rc is when the force is a fully
bonded interaction. GROMACS keeps track of the non-bonded interactions for all
of these particles by using a pairlist. This list contains atoms i, displacement
vectors of these atoms, as well as all the particles j within the radius of atom i.
In order to create this neighbor list, i.e., all particles within the cut-off criteria,
neighbor searching must be utilized. Neighbor searching uses periodic boundary
conditions which allows for the use of a grid search. Figure 30 shows a grid search
in two dimensions.13
Figure 30. Grid search.13
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3.2.7 Output Control
The output control gives commands on when to update certain files. There are
five commands: nstxout, nstvout, nstxtcout, nstenergy, and nstlog. nstxout gives
the frequency on when to write coordinates to the output trajectory file. nstvout
writes velocities to the output trajectory file. nstxtcout writes coordinate to the xtc
trajectory file. nstenergy writes energies to the energy file. Finally, nstlog writes
energy to the log file. In all cases except nstxtcout, the last parameters are always
written.13 Updating files occurred every 1000 steps.
3.2.8 Temperature Coupling
Because we intended to simulate a system that contained a constant
temperature, i.e., 293 K, 310 K, 323 K, and 348 K, we used a constant temperature
ensemble, NVT. A thermostat was needed to ensure proper sampling of this
canonical ensemble at constant temperature. Temperature, which reflects the
average energy, i.e., kinetic energy, of the system, is calculated through the
equipartition function. Therefore, a thermostat is needed to guarantee that the
average temperature is correct.
There are different thermostats to choose from within GROMACS. These
include weak coupling scheme of Berendsen, extended ensemble Nose´-Hoover scheme
or the velocity rescaling scheme. We chose the velocity rescaling scheme, also known
as V-rescale, for studying α-synuclein in water and the Nose´-Hoover scheme for
studying carbon nanotubes. Both will be discussed.
The velocity rescaling scheme is a modification of the Berendsen so this
thermostat will first be described. Berendsen temperature coupling mimics that of
first-order kinetics of an outside heat source with a temperature of To. The
difference in temperature of the system to the external heat source is slowly
corrected through equation 3.14.
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dT
dt
=
To − T
τ
(3.14)
From equation 3.14, the temperature difference decays exponentially with a
time constant τ . The strength of the coupling can be varied depending upon the
work needed. For equilibration, the coupling time can be short, i.e. 0.01 ps.
However, for reliable equilibrium simulations, the time may be much longer, i.e. 0.5
ps.
The disadvantage of using the Berendsen thermostat is that it suppresses the
fluctuations of the kinetic energy, and, therefore, will not produce an accurate
canonical ensemble. However, a thermostat that does produce an accurate NVT
ensemble is the velocity rescaling thermostat.
The velocity rescaling thermostat uses an additional stochastic term that
creates an accurate kinetic energy distribution, see equation 3.15, thus producing a
correct NVT ensemble.
dK = (Ko −K) dt
τT
+ 2
√
KKo
Nf
dW√
τT
(3.15)
Here K is the kinetic energy, Nf is the number of degrees of freedom, and dW
is a Wiener process. The other excellent feature of the velocity rescaling thermostat
is that it takes advantage of the Berensen thermostat in that it is a first order decay
of temperature and there are no oscillations involved.85
The Nose´-Hoover scheme (used for carbon nanotubes)
3.2.9 Pressure Coupling
Just as temperature is able to be coupled, pressure may be coupled to the
system. There are different types of algorithms that can be used such as the
Berendsen algorithm, extended ensemble Parrinello-Rahman, and the
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Martyna-Tuckerman-Tobias-Klein (MTTK). We chose the Parrinello-Rahman
algorithm, which can be easily combined with other temperature coupling
algorithms.
During the NVT equilibration, pressure coupling was turned off. However,
during the NPT equilibration, pressure coupling was turned on in order to
equilibrate pressure using the Parrinello-Rahman approach.
The Parrinello-Rahman pressure coupling will provide constant pressure
simulations, and, in theory, give an accurate NPT ensemble. This barostat obeys
the matrix equation of motion in equation 3.16
db2
dt2
= VW−1b
′−1(P−Pref ) (3.16)
where the box vectors are represented by the matrix b, V is the volume of the
box, W is the matrix parameter that controls the strength of the coupling, and P
and Pref are the current and reference pressures, respectively.
For the particles, the equations of motion are altered. Under normal
circumstances, both the Nose´-Hoover thermostat and the Parrinello-Rahman
barostat are applied. For simplistic purposes, the Parrinello-Rahman modification is
shown in equations 3.17 and 3.18.
d2ri
dt2
=
Fi
mi
−Mdri
dt
(3.17)
M = b−1
[
b−1
db′
dt
+
db
dt
b′
]
b′−1 (3.18)
The inverse mass parameter matrix W-1 figures two things: the strength of the
coupling and how the box can be deformed. It is defined by equation 3.19
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(
W−1
)
ij
=
4pi2βij
3τ 2pL
(3.19)
where β is the isothermal compressibility, τp is the pressure time constant, and
L is the largest box matrix element.86,87
3.3 Important properties
3.3.1 Root Mean Square Deviation
Root mean square deviation (RMSD) was calculated using the program g rms.
This program compares the final structure after molecular dynamics to that of a
reference structure using least-square fitting. Calculating the RMSD is shown in
equation 3.20
RMSD (t1, t2) =
[
1
M
N∑
i=1
mi ‖ri(t1)− ri(t2)‖2
]1/2
(3.20)
where M =
∑N
i=1mi and ri(t) is the position of atom i at position t .
13
RMSD can be calculated based on a number of different regions. For example,
evaluating RMSD could include comparing the main chain, the protein plus
hydrogen atoms, side chains, Cα of the backbone, as well as other regions to the
reference structure and the final structure.13
3.3.2 Radius of Gyration
The radius of gyration measures the compactness of the protein, for example,
how folded or unfolded it is. GROMACS uses the program g gyrate to calculate this
by evaluating he root mean square distance between its center of gravity and its
ends. More specifically, g gyrate calculates the radius of gyration based off of a
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group of atoms, which are mass weighted, and the radii of gyration about the x, y,
and z axes, as a function of time. α-synuclein was fitted along the backbone atoms,
i.e. N, Cα, and C. The equation used to obtain the radius of gyration is seen in
equation 3.21
Rg =
(∑
i ‖ri‖2mi∑
imi
)1/2
(3.21)
where mi is the mass of atom i and ri is the position of atom i with respect to
the center of mass of the molecule.13
3.3.3 Density
Density can be calculated using the program g density. This program calculates
the partial density across the box by considering the masses. This tool becomes
practical when considering the distribution of atoms or groups along the interface.
To determine the density for the entire isothermal- isobaric, i.e. NPT, ensemble, the
program g energy should be used.13
3.3.4 Energies
The program g energy is useful for the verification of some or all energies as
well as different properties, i.e. total pressure, pressure tensor, density, box-volume
and box-sizes, by extracting either energy components or distance restraint data
from an energy file. The result allows the user to choose from a list of set energies
such as potential, kinetic or total energy, or specific contributions such as
Lennard-Jones or dihedral energies.13
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CHAPTER IV
MODELING α-SYNUCLEIN IN AQUEOUS SOLUTIONS
4.1 Force fields
A force field represents the parameters of a potential that are used to calculate
forces in molecular dynamics simulations. The goal in the creation of a force field is
to be able to describe interactions between particles, mainly atoms.
4.1.1 Model for alpha-synuclein
The force field applied to one protein of alpha-synuclein to a system of water
was the optimized potential for liquid simulations, all atom model (OPLS-AA). This
force field is based on liquid-state simulations88 and has been shown to correctly
compute liquid state thermodynamic properties.89
Most force fields divide potential functions into two categories: bonded and
nonbonded interactions. Bonded interactions include covalent bond-stretching,
angle-bending and torsion potentials. Nonbonded interactions include
Lennard-Jones repulsion and dispersion as well as electrostatics.12 For the
OPLS-AA, the nonbonded parameters, i.e., charge–charge and van der Waals terms,
were calculated from liquid state calculations. However, bonded parameters, i.e.,
stretching, bending, and torsional terms, were fitted using quantum chemical
calculations.88
The total energy of the system is calculated as the sum of the nonbonded
energy, bond stretching and angle bending terms, and torsional energy, see equation
4.1.
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Etotal = Enonbonded + Ebond + Eangle + Etorsion (4.1)
We will first look at the bonded interactions and then the nonbonded
parameters.
Like mentioned previously, bonded parameters consist of bond-stretching,
angle-bending, and torsion potentials. Both bond-stretching and angle-bending are
depicted in Figure 31.
Figure 31. Bond stretching and angle bending between atoms i, j, and k.15
Bond stretching is defined by harmonic potentials. Harmonic potentials are
both strong and fluctuate little around their equilibrium values, see Figure 32
below. The potential can be described through a parabolic equation, equation 4.2.
Figure 32. Harmonic Potential. Shows a deep well around the equilibrium bond
length.16
V =
1
2
k(R−Req)2 (4.2)
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where k is the force constant, R is the bond length and subscript eq refers to
equilibrium values. The bond equilibrium values are found through x-ray data while
force constants are derived by fitting to experimental vibrational frequency data.15
Below, equations 4.3 and 4.4 are the equations used to obtain bond stretching and
angle bending energies.
Ebond =
∑
bonds
Kr(r − req)2 (4.3)
Eangle =
∑
angle
KΘ(θ − θeq)2 (4.4)
where r is bond length, θ is bond angle, and K encompasses the force constant.
The torsional term is described in equation 4.5 and is summed over all of the
dihedral angle, i.
Etorsion =
∑
i
V 1i
2
[1 + cos(φi)] +
V i2
2
[1− cos(2φi)] + V
i
3
2
[1 + cos(3φi)] (4.5)
A dihedral angles is shown in Figure 33.
Figure 33. Dihedral angle. Defined by three bond vectors.17
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The dihedral potential, V , is represented by a cosine expansion. Because the
dihedrals are free rotating, the angle may have any value within 360◦ but this
depends on the barrier between low energy conformations.90
The nonbonded energy was calculated as the sum of the Coulomb and
Lennard-Jones contributions for pairwise intra- and intermolecular interactions88 as
shown in equation 4.6.
Enonbonded =
∑
i<j
[
qiqje
2
rij
+ 4ij
(
σ12ij
r12ij
+
σ6ij
r6ij
)]
fij (4.6)
Coulomb’s law, first part of equation 4.6, describes the electrostatic interaction
between two point charges, i.e., atoms i and j.91 This can be seen in the first part of
the above equation where e is known as the Coulomb’s constant, electric force
constant, or electrostatic constant and rij is the distance separating the two point
charges. The Coulomb’s constant was derived by Maxwell using the speed of light,
magnetic permeability and electric permittivity. The attractive and repulsive forces
are also described by Coulomb’s law because if both point charges are the same,
there is repulsion. If both, however, have opposite charges, they are attracted
towards each other.
The Lennard-Jones potential takes into account the van der Waals forces
because of dipole-dipole interactions as well as Pauli repulsion due to repulsive
forces.15 An example of a Lennard-Jones potential can be seen in Figure 34. As a
molecule moves closer to another molecule, their electrons and nuclei interact with
each other causing a potential energy of interaction. The potential increases
dramatically as two particles move closer than their equilibrium bond length and,
thus, repulsion occurs. The potential decreases as two particles move farther away
from their equilibrium bond length and, thus, attraction occurs.18
The Lennard-Jones potential term can be seen in the second part of equation
4.6. Here, ij is the depth of the potential well, σij is the distance between atoms i
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Figure 34. Lennard-Jones Potential.18
and j where the inter-particle potential is zero, rij is the distance between atoms i
and j, and fij is a scaling factor.
88 This ”6–12” potential has both an attractive,
sixth-power, and repulsive, twelfth-power, term. The scaling factor is used to limit
computational time as it would not need to consider every bonded interaction, i.e.
energy would be zero. fij is 0 when atoms i and j are either connected by one or two
valence bonds, i.e. 1–2 or 1–3 pairs. fij is 0.5 when the atoms are connected
through three bonds, i.e. 1, 4 interactions, and 1.0 for all other interactions.
Combination rules for the parameters, σij and ij, are used to help describe the
interaction energy between two different non-bonded atoms, i.e. i and j. There are
many different types of combination rules and knowing which one to use is based on
the force field being utilized. The geometrical average works best with the chosen
force field, optimized potential for liquid simulations, all atom model.88 The
geometrical average is given by equations 4.7 and 4.8
σij = (σiiσjj)
1
2 (4.7)
ij = (iijj)
1
2 (4.8)
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4.1.2 Water Model
There are many different solvent models to choose from. In our simulations, we
used water as the solvent. The water models are classified by the amount of points
used to describe the model (which can range from 2-site to 6-site models), the
flexibility of the molecule, as well as the polarization effects. For water models, the
most common are SPC, SPC/E, TIP3P, and TIP4P. For our solvent, we chose the
three-site model, SPC/E (Simple Point Charge Extended model), which is a
modification of SPC. This provides a better density and diffusion constant than the
SPC model. The result is that the SPC/E model provides simplicity and
computational efficiency for molecular dynamics. SPC/E is a three-site model,
which is characterized as having three interaction sites, correlating to three atoms
(two hydrogens and one oxygen). A point charge is appointed to each atom, plus
oxygen receives the Lennard-Jones parameters. The SPC/E assigns a rigid
geometry, i.e planar, instead of assuming an ideal tetrahedral shape. Figure 35
shows a water molecule as defined by the SPC/E model. Table 2 lists the different
parameters used for the SPC/E water model where σ is the Lennard-Jones
parameter for oxygen, and q1 and q2 are the charges of hydrogen and oxygen
respectively.23
Figure 35. Simple Point Charge Extended (SPC/E) Model.19
54
Table 2. Parameters of the SPC/E water model.23
Parameters SPC/E
σ(A˚) 3.166
(kJmol−1 0.650
l1(A˚) 1.000
q1(e) +0.4238
q2(e) -0.8476
θ◦ 109.47
4.2 Set-up
4.2.1 Energy minimization
Four simulations were ran at different temperatures: 293 K, 310 K, 323 K, 348
K. The energy of the entire system was minimized using the command, mdrun, see
Figure 36 below. The potential energy reached an adequate plateau of
-1.025x109kJmol−1 to ensure no steric clashes or inappropriate geometries.
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Figure 36. Energy Minimization
The energy minimized system can be seen in Figure 37.
56
Figure 37. Energy minimization of the aqueous system where the tubes are the alpha-
helices, black regions are the coils, and violet regions are the turns. Blue spheres are
represented as sodium ions.
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4.2.2 NVT Equilibration
The systems were equilibrated to the set temperatures, see Figure 38 and Table
3, by using the velocity rescaling thermostat and the program in GROMACS,
mdrun.
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Figure 38. Temperatures for four different simulation runs.
The resulting configurations of α-synuclein in the four different systems are
illustrated in Figure 39. There is not much deviation amongst the structures.
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Table 3. Average temperature and standard deviation associated with each simula-
tion.
Tsim, K <T>, K σ
293 292.82 4.97
310 309.78 5.31
323 322.75 5.57
348 347.70 6.08
Figure 39. Configurations of α-synuclein at four different simulation runs. Here, the
alpha helices are denoted by red, bet a bridges are denoted by orange, turns are
denoted by violet, and coils are denoted by black.
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4.2.3 NPT Equilibration
Pressure was also equilibrated, in all systems, to 1 bar by using the pressure
coupling of the Parrinello-Rahman barostat. The GROMACS program, mdrun, was
also utilized. There were large fluctuations of pressure, see Figure 40, due to it
being a macroscopic property. This property can only be measured through a time
average. The variation as well as the speed of oscillation depends on the number of
atoms in the system (decreases by the number of particles), the type of pressure
coupling used, and the value of pressure coupling constants.13 Since all four different
simulations were equilibrated to around 1 bar, see Table 4, only one plot was shown
to illustrate this. In both pressure and temperature equilibration simulations, the
number of steps was 5,000 which was equivalent to 100 ps.
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Figure 40. Pressure for the simulation at 310K.
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Table 4. Average pressure and standard deviation associated with each simulation.
Psim <P>, bar σ
P293 1.05 34.50
P310 0.974 34.82
P323 0.989 34.96
P348 1.0712 42.68
From the temperature and pressure data, density could be calculated using
g energy, see Figure 41 below. The results were as expected since at colder
temperatures, i.e., 293 K, the protein would constrict, and, at higher temperatures,
i.e., 348 K, the protein would become more relaxed, thus having a lower density.
Figure 41. Density for all four simulations.
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Table 5 displays the average and standard deviations of the different densities.
Table 5. Average density and standard deviation associated with each simulation.
Tsim, K < ρ >, kg/m
3 σ
293 1002.91 0.72
310 994.08 0.61
323 986.02 0.88
348 968.29 1.86
4.3 Properties of α-synuclein
4.3.1 RMSD
For the RMSD calculation, we compared the backbone of the protein to the
reference structure and the final structure, as can be seen in Figure 42. Our
reference structure was that of the initial .pdb structure obtained from the Protein
Data Bank once it was minimized in the equilibrated system, see Figure 36. The
RMSD compared to the equilibrated α-synuclein indicates that the protein is not
stable as their is no plateau.
62
0 5 10 15
Time (ns)
0
1
2
3
4
5
R
M
SD
 (n
m)
293K
310K
323K
RMSD
1XQ8, Backbone
Figure 42. RMSD at four different temperatures.
4.3.2 Radius of gyration
The radius of gyration at four different temperatures is given in Figure 43. At
all four simulations, α-synuclein appears to fold and unfold over time, resulting in
an unstable conformation. This can clearly be seen in Figure 44 as the final
configuration is shown for each simulation.
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Figure 43. Radius of gyration at four different temperatures.
Figure 44. Ending configurations of α-synuclein.
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4.4 Conclusion and future work
Molecular simulations of α-synuclein in water at four different temperatures,
i.e., 293 K, 310 K, 323 K, and 348 K, were studied using GROMACS, a molecular
dynamics package. Energy minimization was first used to ensure no steric clashes or
inappropriate geometries for the electroneutral system. The potential energy
plateaued to around −1.025x109 kJ mol−1. Energy minimization was followed by
equilibration of both temperature and pressure, using a correct ensemble, which
allowed for the determination of density. Molecular dynamics were then employed to
study the trajectory of the protein. Analysis showed the RMSD of all four proteins
at the different temperatures were not stable compared to that of the equilibrated
protein. The radius of gyration indicated that the protein was folding and unfolding.
In the future, we hope to simulate the aggregation of α-synuclein in an aqueous
environment. This would be done through Wang-Landau (WL) sampling with
Monte Carlo (MC) simulations. Furthermore, we intend to simulate α-synuclein in a
lipid bilayer, since this is where it is naturally found, Figure 45. Lipid parameters
have been written and can be easily incorporated within GROMACS. Molecular
dynamics could then be used to study the trajectory of the protein through time.
Finally, aggregation could be observed within the bilayer system using WL sampling
and MC simulations.
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Figure 45. Future work involving α-synuclein, a libid bilayer, water, and ions.
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CHAPTER V
DRUG DELIVERY FOR NEURODEGENERATIVE DISEASE
5.1 Case study: Amantadine
As mentioned previously in the Introduction, there have been no cures for any
of the neurodegenerative diseases mentioned, only drugs that help slow the
progression and manage symptoms. An array of different drugs have been proposed
for the controlling of symptoms of Parkinson’s disease. One such class of drugs are
the aminodamantanes. It was thought, from the 1960s to the late 1980s, that these
drugs managed symptoms of PD through dopaminomimetic activity. It was not
until the 1990s that a new mechanism, and, therefore, a new therapeutic approach
appeared, i.e. N-methyl-D-aspartate (NMDA) receptor antagonism.92
The aminodamantane’s, such as amantadine (Figure 46), role in Parkinson’s
disease is due to its inhibition of NMDA receptors,93 see Figure 47. This receptor,
which is a specific type of ionotropic glutamate receptor, is found in the basal
ganglia; it is important for the general nature of the central nervous system and
could have an impact on learning and memory.94 This type of receptor is an object
of interest for the development of drugs for Parkinson’s disease because of the
critical dopamine-glutamate interactions.95 NMDA receptors respond to glutamate
(an essential excitatory transmitter existing in the brain) and are termed based on
their selective agonist, N-methyl-D-aspartate.96 When amantadine binds to this
receptor, it causes a blockage in the channel’s receptors.97–100 This, then, causes the
channel gates to close at a higher rate resulting in an impediment of current flow
through the receptor’s channels.101
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Figure 46. Amantadine, also known as 1-aminoadamantane.
Figure 47. NMDA receptor. This receptor can be influenced by a number of antag-
onists including: competitive antagonists at the glycine and glutamate binding sites,
as well as non-competitive NMDA receptor channel blockers. When an antagonist
binds to either the glycine or glutamate site, the channel is blocked from activation
and opening.20
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Single walled carbon nanotubes (SWCNs) have been used in the drug delivery
system (DDS) because of the advancement of the carbon nanotube (CNT)
solubility. CNTs, themselves, have large inner volume resulting in the possibility of
being nano-drug carriers or nanovectors for drug delivery.102–105 SWCNs are able to
be used with various drugs and proteins because of their ability to be chemically
functionalized. The nanotubes also have a particular size and shape that enables
them to selectively cross biological barriers allowing them to be a great resource for
DDS applications.102,106–108
Four SWCNs were selected in order to study the affects of adsorption and
diffusion within the nanomaterial: SWCN (8,8), SWCN (12,12), SWCN (16,16), and
SWCN (20,20), with diameters ranging from 10.9 A˚ to 27.1 A˚. SWCNs can be
thought of as wrapping a one-atom-thick layer of graphene into a seamless tube. The
way the carbon nanotubes are rolled can result in different shapes, and, therefore, a
naming system using a pair of indices (n,m) occurred. Figure 48 shows the naming
convention for these nanoporous structures. One structure that can be produced is
the zigzag (n,0) structure, Figure 49. This develops when the carbon-carbon bonds
are parallel to the cylinder’s axis and creates an open end, ”zig-zag” pattern. In
Figure 48, this could be represented by rolling (0,0) to (7,0), creating SWCN (7,0).
The next structure that can be produced is the armchair arrangement, see Figure
49. This occurs when n equals m creating carbon-carbon bonds that are
perpendicular to the cylinder’s axis. For example, in Figure 48, one would roll (0,0)
to a point represented by n = m, e.g., (5,5). This nanomaterial would then be
labeled as SWCN (5,5). Both of these structures are classified as achiral since they
have a superimposable mirror image. The last structure that could be produced are
chiral, Figure 49, when n does not equal m and neither indices are equal to 0. For
example, rolling (0,0) to (5,2) would produce SWCN (5,2).21
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Figure 48. Labeling convention for SWCNs.21
Figure 49. SWCNs possible shapes. Armchair occurs when n = m resulting in
carbon-carbon bonds being perpendicular to the tube’s axis. Zigzag (n,0) where the
carbon-carbon bonds are parallel to the tube’s axis. Chiral occurs when m 6= n.22
The transport mechanism of these SWNCs have been difficult to explore
experimentally. We, therefore, have studied the adsorption and diffusion of these
nanomaterials.
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5.2 Adsorption and diffusion in single-walled carbon nanotubes
5.2.1 Expanded Wang-Landau simulations
Due to the difficulty of studying large drug molecules adsorbing into
nanoporous materials, different methods have arised. One such method is finding
the preferred orientations and/or positions of the molecule and then inserting it into
the nanomaterial.84 Another method, which we used, was the Expanded
Wang-Landau (EWL) simulations. We chose this method because it allows for (1) a
uniform sampling of the number of molecules, i.e. amantadine, adsorbed in a porous
material, i.e single-walled carbon nanotubes (SWCN), (2) the insertion/deletion of
large molecules by dividing the insertion and deletion of molecules into a large
number of steps and (3) the determination of a highly accurate estimate of the
grand canonical partition function for the system. The method, which will be
illustrated below, has been shown to produce accurate results recently.109,110
In order to describe Expanded Wang-Landau (EWL) simulations,
Wang-Landau (WL) sampling will first be described.
Wang-Landau sampling allows for all number of particles N to be sampled
evenly. In traditional Monte Carlo (MC) methods, Boltzmann sampling is used.
The drawback of this is that there is a very low probability for the system to have
an order parameter between the vapor and liquid states, which causes sampling to
be uneven as the simulation would get stuck in one state or the other, Figure 50.
The use of WL sampling allows us to bias the probability function which then has
the same probability function value over the specified range, Figure 51. This, then,
allows for all states of the system to be sampled equally.111,112
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Figure 50. Boltzmann sampling.
Figure 51. Wang-Landau sampling.
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The Expanded Wang-Landau method uses the simplified expanded
grand-canonical (SEGC) partition function so the derivation of this function will
first be described.
The canonical partition function is described by equation 5.1
Q(N, V, T ) =
V N
N !Λ3N
∫
exp(−βU(Γ))dΓ (5.1)
where there are N molecules, at volume V, temperature T, Λ = h/
√
2pimkBT is
the thermal de Broglie wavelength and U (Γ) is the internal energy of the system of
N molecules in the specific configuration, Γ. The integration is performed over Γ,
thus over the coordinates of the N molecules of the system.
We can then use equation 5.1 to obtain the grand canonical partition function
given in equation 5.2.
Θ(µ, V, T ) =
∞∑
N=0
Q(N, V, T )exp(βµN), (5.2)
where µ is the chemical potential, β = 1
kBT
.
In order to obtain the expanded grand canonical (EGC) partition function,
insertion and deletion of molecules needed to be accounted for through an efficient
scheme, which would result in a change of N. In order to do this, insertion and
deletion were divided into M different stages, where M is an integer. The system,
during the simulation, would have both N molecules as well as a fractional particle
in stage l, where 0 ≤ l ≤ M− 1. The fractional molecule is allowed to interact with
full particles by a coupling parameter ξl. Throughout the simulation, l is allowed to
change causing N to change as well. In order to account for the fractional molecule
plus N molecules, the grand-canonical partition function was expanded. To do this,
(i) the sum over all N and l were taken instead of only N and (i) a weighting
function, denoted by ψ (l,N ), is added. The weighting function is normally
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determined through numerical calculations113–115 which allows for the optimization
of the sampling of the system around a specific value N. The expanded grand
canonical (EGC) partition function116–122 is then given by equation 5.3
109
ΘEGC(µ, V, T ) =
∞∑
N=0
M−1∑
l=0
Q(N, V, T, l)exp(βµN + ψ(l, N)) (5.3)
where Q(N,V,T,l) is the canonical partition function for a system of N full
particles and a fractional particle at stage l > 0 given by
Q(N, V, T, l) =
V N+1
N !Λ3NΛ3l
∫
exp(−βU(Γ))dΓ (5.4)
where Λl is the thermal de Broglie wavelength for a fractional particle in stage l
> 0 and Γ represents a specific configuration of the system made up of N full
particles and a fractional particle.
Simplifying the EGC partition factor enables the simulations to converge faster.
To do this, we let ψ(l,N ) = 0 for all l and N since the weighting function has no
affect on the grand-canonical partition function because the Wang-Landau sampling
is used, i.e., samples uniformly. Also, we let the mass of the fractional particle be
the same as the full particle, and therefore Λl = Λ. The partition function of a
simplified grand canonical (SEGC) ensemble can then be seen in equation 5.5
ΘSEGC(µ, V, T ) =
∞∑
N=0
M−1∑
l=0
Q(N, V, T, l)exp(βµN) (5.5)
where the canonical partition function for or 0 < l < M is as follows
Q(N, V, T, l) =
V N+1
N !Λ3N
∫
exp(−βU(Γ))dΓ (5.6)
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The Wang-Landau sampling is now applied within the SEGC partition
function. Having a fractional particle l, there are two possibilities for the joint
Boltzmann distribution depending on the value of l,
p(Γ, N, l) =

V N+1exp(βµN−βU(Γ))
N !Λ3(N+1)ΘSEGC(µ,V,T )
for 0 ¡ l ¡ M
V N exp(βµN−βU(Γ))
N !Λ3NΘSEGC(µ,V,T )
for l = 0
(5.7)
Then, the probability distribution, p(N, l), can be obtained by equation 5.8
p(N, l) =
∫
p(Γ, N, l)dΓ =
Q(N, V, T, l)exp(βµN)
ΘSEGC(µ, V, T )
(5.8)
The biased distribution for 0 < l < M is then
pbias(Γ, N, l) =
p(Γ, N, l)
p(N, l)
=
V N+1exp(βµN−βU(Γ))
N !Λ3(N+1)ΘSEGC(µ,V,T )
Q(N,V,T,l)exp(βµN)
ΘSEGC(µ,V,T )
=
V N+1exp(−βU(Γ))
Q(N, V, T, l)N !Λ3(N+1)
and the biased distribution for l = 0 is as follows
pbias(Γ, N, l = 0) =
p(Γ, N, l = 0)
p(N, l = 0)
=
V N exp(βµN−βU(Γ))
N !Λ3NΘSEGC(µ,V,T )
Q(N,V,T,l=0)exp(βµN)
ΘSEGC(µ,V,T )
=
V Nexp(−βU(Γ))
Q(N, V, T, l = 0)N !Λ3N
(5.9)
The MC acceptance criterion from an old state (Γo, No and fractional number
lo) to a new state (Γn), Nn and ln) is given generally by
acc(o→ n) = min
[
1,
pbias(Γn, Nn, ln)
pbias(Γo, No, lo)
]
(5.10)
Specifically, there are four different MC acceptance criteria depending on both
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the value of l and if the adsorbates are atoms or molecules. In our case, we deal
with molecular fluids, so the internal degrees of freedom of rotation and vibration,
qint need to be accounted for. The acceptance criteria is then
acc(o→ n) = min
[
1,
Q(No, V, T, lo)V
NnqNnintNo!Λ
3Noexp(−βU(Γn))
Q(Nn, V, T, ln)V Noq
No
intNn!Λ
3Nnexp(−βU(Γo))
]
(5.11)
The WL sampling algorithm in the SEGC ensemble now works by estimating
the value of Q(N, V, T, l) and visiting both values of N and fractions l. Two
different histograms are kept. One histogram is used to keep track of the visited
values of N while the other keeps track of the visited values of l. When the
simulation has finished converging, Q(N, V, T, l) is provided up to a multiplicative
constant. Because Q(N = 0, V, T, l = 0) = 1, Q(N, V, T, l) can then be obtained.
The grand canonical partition function is then ascertained by using a Laplace
transform as seen in equation 5.12
Θ(µ, V, T ) =
∞∑
N=0
Q(N, V, T, l = 0)exp(βµN) (5.12)
The use of EWL simulations allowed us to study adsorption of amantadine in
single-walled carbon nanotubes (SWCNs) at T = 298 K.
Through EWL simulations, we found the absolute adsorbed of amantadine
within the nanotube by equation 5.13
Nads =
∞∑
N=0
Np(N) (5.13)
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5.2.2 Adsorption isotherms for Amantadine
Amantadine loading can be seen in Figure 52 where the loading is denoted in
mg of amantadine per gram of SWCN. The loading is expressed as a function of
reduced pressure P/P0 where P0 is the vapor pressure of amantadine at 298 K.
123
Figure 52. Adsorption isotherms of amantadine at T = 298K at four different SWCNs.
We can see by both Figure 53 and Table 6, that the amount adsorbed is
dependent upon the diameter of the single-walled carbon nanotubes - the larger the
diameter, the better the adsorption of amantadine. Looking at Figure 53, it is
noted that as the diameter of the nanotube decreases, the isotherm step is shifted
towards lower pressure. This effect can be seen especially when the SWCN becomes
roughly the same size as the amantadine molecule, i.e., SWCN (8,8). This is
consistent with other findings when GCMC simulations were used to study the
adsorption of N2 in single-walled carbon nanotubes.124
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Table 6. Loading based off of different SWCNs.
SWCNs Diameter (A˚) Loading (mg/g)
SWCN (8,8) 10.9 131
SWCN (12,12) 16.3 250
SWCN (16,16) 21.7 412
SWCN (20,20) 27.1 554
Figure 53. Amantadine adsorbed in single-walled carbon nanotubes at T = 298 K
and P = P0 for (a) SWCN (8,8), (b) SWCN (12,12), (c) SWCN (16,16), and (d)
SWCN (20,20).
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To explore amantadine’s structure when acting as the adsorbed fluid, we
plotted the density profiles obtained at all four nanotubes at the saturation
pressure, see Figure 54. The density profiles were found using equation
ρ(R) =
< N(R,R + ∆R) >
pi((R + ∆R)2 −R2)L (5.14)
where < N(R,R + ∆R) > is the average number of amantadine molecules
within the cylindrical shell, enclosed between the two cylinders of radii R and R +
∆R. The radius interval ∆R is equal to one hundredth of the nanotube’s radius.
Figure 54. Density profiles for amantadine adsorbed in single-walled carbon nan-
otubes at T = 298 K and P = P0 for (a) SWCN (8,8), (b) SWCN (12,12), (c) SWCN
(16,16), and (d) SWCN (20,20).
We observed a single peak for SWCN (8,8) located on the central axis of the
nanobute indicating that the system was organized in a ”line” along the axis of the
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nanotube. This can also be seen in Figure 55a. Another single peak for SWCN
(12,12) was observed where the maximum occurred at 3.3 A˚. However, the structure
that resulted, Figure 55b, was different when compared to SWCN (8,8). For the
smallest diameter, i.e., SWCN (8,8), amantadine is organized into a single layer,
taking the shape of the cylindrical tube. When the diameter is allowed to increase,
the confined amantadine’s structure evolves. Looking at both SWCN (16,16) and
SWCN (20,20), it was observed through the density profile, Figure 54c and d, that
both nanotubes featured two peaks. For SWCN (16,16), one peak occurred at the
central axis of the nanotube while the other occurred around 6.1 A˚. The resulting
structure, seen in Figure 55c, shows a bilayer-type of structure - one layer occurring
along the the ”line” of the axis of the nanotube and the other occurring as a
cylindrical layer around the first. The density profile of SWCN (20,20), Figure 54d,
indicates one peak occurred at 3 A˚ while the other peak occurred at 8.5 A˚. The
corresponding structure can then be seen in Figure 55d. Comparing SWCN (16,16)
and SWCN (20,20), the larger diameter, i.e., SWCN (20,20), contained more than
the bilayer structure that was observed for SWCN (16,16), but it was not large
enough to result in two cylindrical layers around the single layer at the axis.
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Figure 55. Structures for amantadine when adsorbed in single-walled carbon nan-
otubes at T = 298 K and P = P0 for (a) SWCN (8,8), (b) SWCN (12,12), (c) SWCN
(16,16), and (d) SWCN (20,20).
5.2.3 Diffusion process for Amantadine
Next, we looked at the diffusion process using molecular dynamics. During the
simulations, the axial positions, i.e., along the z-axis, were stored and later used
when the post-processing of the simulations in order to characterize self-diffusion
occurred. Self-diffusion in single-walled carbon nanotubes is defined by equation
5.15 as the long-time self-diffusivity Ds in the axial (z) direction.
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lim
t→∞
〈
1
N
N∑
i=1
[zi(t)− zi(0)]2
〉
= 2Dst (5.15)
We plotted the average mean square displacement along the axis of SWCN
(16,16) against time on a linear plot using various loadings of amantadine ranging
from 47 mg/g to 280 mg/g, Figure 56a. At short times, we observed the expected
behavior as the system was in the ballistic regime. At intermediate times, the
system changed to being in the subdiffusive regime, as expected. Finally, the
Fickian regime was ascertained. The Fickian regime is characterized when the mean
square displacement shows linear variation against time. The slope is then related
to the self-diffusivity Ds based on equation 5.15.
While in the Fickian regime, we calculated the turnover point as seen in
equation 5.16.
d log < (z(t)− z(0))2 >
d log t
= 1± 0.15 (5.16)
We then used this to graph the turnover points for three different loadings of
amantadine in SWCN (16,16), Figure 56b.
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Figure 56. (a) RMSDs at various loadings of amantadine within SWCN (16,16). (b)
LOG-LOG plot of RMSDs showing the expected linear behavior (shown as squares)
in the Fickian regime.
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Finally, we looked at the self-diffusivity Ds for amantadine at SWCN (8,8),
SWCN (12,12), SWCN (16,16), and SWCN (20,20) at various loadings (in mg of
amantadine per g of SWCN), Figure 57. Generally, for all four nanotubes, as the
loading increases, the self-diffusivity Ds decreases. This conceptually makes sense
because as the density of the fluid increases, there would be less diffusion for
amantadine. It was found that the rate at which Ds decreases is dependent upon
the loading for the larger diameter nanotubes, i.e. SWCN (16,16) and SWCN
(20,20). The self-diffusivity of SWCN (16,16) decreases dramatically until the
loading is around 230 mg/g. Comparing the loading of 47 g/mg to that of 234
mg/g, the Ds at 234 mg/g is divided by three. As the loading is increased at 234
mg/g, Ds decreases at a more moderate rate. Between loadings of 234 mg/g and
412 mg/g, Ds decreases by 25%. When looking at SWCN (20,20), Ds decreases
dramatically until the loading si around 300 mg/g. Comparing the loadings of 150
mg/g to 300 mg/g, Ds is divided by 2.3. Ds then decreases at a moderate rate at
higher loadings, i.e. from 300 mg/g to 524 mg/g; decreasing by 15%. The various
changes in the rate at which Ds decreases, can be attributed to the structural
changes that are taking place within the nanotubes. When loading is increased, the
adsorbed amantadine molecules transition from being in a single layer system to
being in a bilayer system. Being in a single layer structure as the loading is
increased causes an increase in the density of the outer cylindrical layer resulting in
the dramatic decrease of Ds. Once the transition occurs and the system has a
bilayer structure, amantadine molecules aggregate to the center of the nanotube.
When loading is increased, there is a much more moderate decrease in Ds.
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Figure 57. Self-diffusivities of amantadine adsorbed at the four different SWCNs as
a function of the loading.
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5.3 Conclusion and future work
Expanded Wang-Landau (EWL) simulations were used to study the adsorption
of amantadine in four different single walled carbon nanotubes (SWCNs). EWL
simulations allowed for the determination of the grand canonical partition function,
which then assisted in the computation of thermodynamic properties. Depending
upon the diameter and the amantadine loading, different structures arose.
Monolayers, which occurred for high loadings and small SWCNs, i.e., SWCN (8,8)
and SWCN (12,12), were characterized as either a line of amantadine along the
central axis or a cylindrical layer appearing close to the inner surface. The second
structure that appeared were bilayers. Bilayers, which occurred for high loadings
and large SWCN, i.e., SWCN (16,16) and SWCN (20,20), were characterized as
having both a line of amantadine along the central axis and a cylindrical layer close
to the inner surface of the nanotube. Finally, self-diffusion was studied to look at
amantadine’s transport. For larger SWCNs, there was a dramatic decrease in the
rate of self-diffusion as a function of increased amantadine loading followed by a
moderate decrease. This was associated to a transition of the amantadine fluid from
a monolayer to a bilayer.
The molecular simulations applied to this system resulted in accurately
predicting adsorption and diffusion properties of amantadine at the four SWCNs.
We hope to further this study by looking at the interactions of dopamine as well as
looking further into the drug delivery of amantadine to the NMDA receptor.
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CHAPTER VI
GENERAL CONCLUSIONS
Molecular simulations are a useful tool for the study of biological systems. Due
to the costliness and difficulty of experimental studies, molecular simulations
provide a great advantage in that they can help predict what phenomena will occur.
From this outcome, experimental studies can use the knowledge to fine tune their
techniques. We have applied molecular simulations to key aspects of
neurodegenerative diseases where we studied α-synuclein in an aqueous environment
as well as amantadine in single-walled carbon nanotbues (SWCNs). It was found for
α-synuclein that at four different temperatures, the protein was unstable, folding
and unfolding through time. For amantadine, different configurations of amantadine
were observed depending upon the diameter of the nanotube as well as the loading.
The self-diffusion coefficients changed dramatically when the transition of the
amantadine fluid from a monolayer to a bilayer occurred.
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